What Is an ATM Offering in Biotech Stocks?

ATM stands for at-the-market offering. An ATM offering allows a public company to sell new shares gradually into the open market at prevailing market prices.

How an ATM works

A biotech company enters into an agreement with a sales agent, often an investment bank. The company can then sell shares from time to time through the agent. Investors may not know exactly when ATM sales happen until the company reports them.

Why biotech companies use ATMs

ATMs give biotech companies flexibility. They can raise money after positive trial updates, during periods of high volume, when the stock price is strong, before major catalysts, to extend cash runway or to fund commercialization preparation.

Why ATMs matter before catalysts

If a biotech stock rises before a major readout, management may use an ATM to strengthen the balance sheet. This can be prudent, but existing shareholders may see per-share upside reduced.

ATM example

Suppose a company has a $150 million ATM facility. If it sells shares at $5 per share, it can issue 30 million new shares. If it sells shares at $10 per share, it can issue 15 million new shares.

How to spot ATM risk

Check filings and press releases for terms such as at-the-market offering, equity distribution agreement, sales agreement, shelf registration, prospectus supplement, aggregate offering price and sales agent.

Why ATMs can pressure stocks

ATMs can create selling pressure because new shares are being sold into the market. The impact depends on volume, timing and investor demand.

Is an ATM always bad?

No. An ATM can be a smart financing tool if the company raises money at favorable prices and uses it to create value. The problem is when investors model upside without accounting for future share issuance.

Bottom line

If a company has an active ATM and the stock rallies before a catalyst, assume dilution is possible unless filings prove otherwise.